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Abstract
Background: Inflammation is known to worsen cerebral damage at the acute phase of stroke. In this setting, cell
adhesion molecules (CAMs) play a crucial role mediating migration of immune cells into the infarcted area.
However, their value in long-term outcome prediction for patients with cerebrovascular diseases (CVD) is less
described.
Methods: Levels of four CAMs (E-selectin, P-selectin glycoprotein ligand-1, intercellular adhesion molecule-1, and
vascular cell adhesion molecule-1 (VCAM-1)) and six other known biomarkers (C-reactive protein (CRP), interleukin-6
(IL-6), N-terminal pro-brain natriuretic peptide (NT-proBNP), troponin I, vasopressin-neurophysin 2-copeptin, and
S100 calcium-binding protein B) were measured in a population of patients presenting CVD. Blood collections for
analysis were performed within different time windows after stroke onset: 0–6 h, 6–36 h, 2–3 days, 5–7 days, and 2–3
weeks. Independent associations with poor outcome at 3 months (modified Rankin Scale score > 2) were sought using
univariate and multivariate analysis after adjustments for age and National Institute of Health Stroke Scale score.
Predictive ability of each biomarker has also been assessed with ROC analysis.
Results: One hundred patients were prospectively included whom 75 presented with ischemic strokes, nine with
hemorrhagic strokes and 16 with transient ischemic attacks. During the first 6 h after stroke onset, E-selectin was found
to be an independent predictor of 3-month outcome (odds ratio (OR) =24; 95 % confidence interval (95 % CI), 2–354;
p = 0.022) (area under the curve (AUC) =78 %), as was VCAM-1 during the third week after onset (OR = 8; 95 % CI, 2–37;
p = 0.01) (AUC = 73 %). Associations remained after the exclusion of patients with hemorrhagic strokes and transient
ischemic attacks. Independent associations with outcome were also found for CRP (OR = 5; 95 % CI, 1–22; p = 0.023)
and IL-6 (OR = 5; 95 % CI, 1–17; p = 0.021) at 2–3 days and for NT-proBNP at 6–36 h (OR = 20; 95 % CI, 1–337; p = 0.04).
Conclusions: E-selectin and VCAM-1 were independent predictors of outcome in a population of patients with CVD.
The predictive capability of other biomarkers known to be indicators for prognosis also emerged, confirming the
study’s robustness. CAMs levels could be considered as objective biological criteria for prognosis in CVD.
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Background
For physicians in stroke units to provide the most ap-
propriate care, they need to be able to predict outcome
in patients with cerebrovascular diseases (CVD). At dif-
ferent stages in stroke management, outcome prediction
helps in decision making about reperfusion therapies,
discriminating between patients needing greater moni-
toring, and even the difficult choice between intensive
care measures and withholding treatment. Initial clinical
scores, like the National Institute of Health Stroke Scale
(NIHSS), are reliable tools. However, adding objective
paraclinical parameters to accurate outcome prediction
techniques has remained a challenge [1]. Finding blood
biomarkers independent of other known predictors of
outcome could lead to objective biological criteria ap-
plicable to future prognosis scores. Inflammation is a
consistent reaction of cerebrovascular events. At the
acute phase, it leads to brain swelling and extension of
ischemic area [2]. For this reason, its effect on prognosis
is of high interest. Association with outcome in CVD
has been widely described for some proteins related to
the inflammatory pathway, especially interleukin-6 (IL-6)
and C-reactive protein (CRP) [3, 4]. Cell adhesion mole-
cules (CAMs) play a crucial role to initiate inflammatory
mechanisms soon after cerebral damage, not only during
ischemia [5], but also during hemorrhagic strokes [6].
They promote migration of immune cells across the
blood–brain barrier within the cerebral parenchyma [7].
However, little is known about their predictive ability in
CVD. The value of measuring E-selectin and vascular
cell adhesion molecule-1 (VCAM-1) has only been de-
scribed for predicting nearest evolution of stroke during
acute phase, but it has never been assessed for long-
term outcomes [8]. The aim of this study is to assess, at
different time points during the management of a popu-
lation presenting CVDs, whether CAMs can predict out-
come at 3 months. To back up our results, we
concurrently assessed biomarkers with predictive value
previously demonstrated in the literature, including CRP
and IL-6 [9].
Methods
Recruitment for this prospective cohort study took place
at Geneva University Hospital’s emergency unit in
Switzerland during a period of 2 years.
Patients
For inclusion, patients had to be admitted within 36 h of
the onset of stroke or transient ischemic attack (TIA).
Diagnosis had to be corroborated by a neurologist’s in-
vestigation and cerebral imaging (magnetic resonance
imaging or a computed tomography scan). Exclusion cri-
teria were pregnancy, being a minor, presenting with a
stroke with an undetermined time of onset, cancer, liver
cirrhosis, renal failure, recent myocardial infarction (less
than 3 months previously), and ongoing treatment with
neuroleptics or lithium. Inclusions were not consecutive
but were dependent on the presence of the paramedical
staff in charge of the study (from Monday to Friday dur-
ing usual working hours). Outcome was assessed at 3
months with modified Rankin Scale (mRS) score by a
neurologist.
Blood collection
For each included patient, blood samples were obtained
within the following time windows after onset of the
cerebral event: within the first 36 h, between 48 and
72 h (2–3 days), between days 5 and 7 (5–7 days), and
during the third week (2–3 weeks). In the earliest time
window, the results of blood samples drawn before and
after the sixth hour following stroke onset were dichoto-
mized to create time windows at 0–6 h and 6–36 h. The
first blood sample was drawn before any reperfusion
therapy.
Biomarker measurements
Four CAMs were quantified in each blood sample: E-
selectin, P-selectin glycoprotein ligand-1 (P-selectin),
intercellular adhesion molecule-1 (ICAM-1), and
VCAM-1. The levels of six other biomarkers with known
predictive values were also assessed: CRP, IL-6, N-
terminal pro-brain natriuretic peptide (NT-proBNP),
troponin I, vasopressin-neurophysin 2-copeptin (copep-
tin), and S100 calcium-binding protein B (S100B). All
measurements were performed using immunoassays, as
has been previously described [10], except for copeptin,
which was quantified using the US KRYPTOR compact
PLUS® (Thermo Scientific, BRAHMS, Germany). All
measurements were blinded.
Statistical analysis
All analyses were carried out using IBM SPSS Statistics
software, version 20 (SPSS Inc., Chicago, IL, USA). The
continuous variables described were frequency and
mean ± standard deviation, along with categorical factors
such as frequencies and percentages. The patients were
dichotomized into good (mRS ≤ 2) or poor (mRS > 2)
outcomes. First comparisons between the clinical char-
acteristics and levels of each protein in each group were
carried out at different times using Mann–Whitney,
Chi-Square, and Fischer exact tests as appropriate, with
significance set at p < 0.05. A Bonferroni correction was
used as a post hoc test when a protein obtained a signifi-
cant result, in order to adapt the p-values by the number
of biomarkers (p-value/10). For proteins showing signifi-
cantly different levels between groups, the continuous
characteristic was expressed as a binary factor using the
best cut-off for maximizing sensitivity and specificity
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according to the Youden index criterion (receiver oper-
ating characteristic analysis). For each biomarker with a
poor outcome, an independent association was sought
using univariate and multivariate logistic regressions,
after adjustment for the clinical characteristics found to
be statistically different during the first comparison.
Next, potential independent associations between CAMs
and outcomes, found in the overall population, were
sought using three subgroups: subgroup 1 of patients
presenting with ischemic events only (excluding
hemorrhagic strokes); subgroup 2 of patients with cere-
bral damage only (excluding TIA); and subgroup 3 of
patients with ischemic strokes only (excluding TIA and
hemorrhagic strokes).
Ethics
This study was approved by the local ethics commit-
tee N.A.C. (Neuclid, Apsic, Chirurgie department) of
the Geneva University Hospitals, as study CER05–026
(05–058). It was carried out in accordance with the Dec-
laration of Helsinki principles. Each patient, or a legally
authorized representative, was informed about the study
and gave consent to participate.
Results
One hundred patients were included in this study, of
whom 75 presented with ischemic strokes, nine with
hemorrhagic strokes, and 16 with TIA. A good outcome
was observed in 65 % of these patients. The population’s
clinical characteristics and comparisons according to
outcome are presented in the Table 1. Age (p = 0.007)
and NIHSS score at admission (p < 0.001) were signifi-
cantly higher in patients with a poor outcome. An initial
blood sample was drawn from 35 patients during the
first 6 h following onset. Of the 10 proteins measured,
E-selectin, VCAM-1, CRP, IL-6, NT-proBNP, and S100B
were at significantly higher levels in the group with a
poor outcome in one of the different measuring times
(Table 2, Fig. 1). After multivariate analysis, with adjust-
ments made for age and NIHSS score at admission, ex-
pected independent associations with a poor outcome
did indeed emerge for the known predictors of poor out-
come: CRP (odds ratio (OR) =5; 95 % confidence inter-
val (95 % CI), 1–22; p = 0.023) (area under the curve
(AUC) =83 %) and IL-6 (OR = 5; 95 % CI, 1–17; p =
0.021) (AUC = 75 %) at 2–3 days, and NT-proBNP
(OR = 20; 95 % CI, 1–337; p = 0.04) (AUC = 76 %) at
6–36 h (Figs. 2, 3).
More interestingly, after multivariate analysis, E-
Selectin was found to be an early independent predictor
of poor outcome at 0–6 h at levels > 29 ng/mL (OR = 24;
95 % CI, 2–354; p = 0.022) (AUC = 78 %), whereas
VCAM-1 was a predictor during the 2–3 week measure-
ment at levels > 820 ng/mL (OR = 8; 95 % CI, 2–37; p =
Table 1 Baseline clinical characteristics of the population with comparison according to outcome
Characteristics Total population Good outcome Poor outcome p value
n 100 65 35
Hemorrhagic stroke n (%) 9 (9) 3 (4.6) 6 (17.1)
Ischemic stroke n (%) 75 (75) 46 (70.8) 29 (82.9)
TIA n (%) 16 (16) 16 (24.6) 0 (0)
Age mean ± SD, years 66 ± 15 63 ± 15 72 ± 13 0.007a
Male n (%) 55 (55) 40 (61.5) 15 (42.9) 0.073b
NIHSS score mean ± SD 7.91 ± 6.42 5 ± 4 14 ± 5 <0.001a
SBP mean ± SD, mmHg 154 ± 29 151 ± 29 160 ± 28 0.101a
DBP mean ± SD, mmHg 85 ± 15 85 ± 14 85 ± 16 0.960a
Hypertension n (%) 63 (63) 39 (60) 24 (68.6) 0.397b
Dyslipidemia n (%) 36 (36) 26 (40) 10 (28.6) 0.256b
Diabetes n (%) 13 (13) 6 (9.2) 7 (20) 0.210c
Tobacco n (%) 43 (43) 30 (46.2) 13 (37.1) 0.385b
Alcohol n (%) 2 (2) 0 (0) 2 (5.7) 0.120c
Oral contraceptive n (%) 1 (1) 1 (1.5) 0 (0) 1.000c
Migraine n (%) 4 (4) 4 (6.2) 0 (0) 0.295c
Atrial fibrillation n (%) 33 (33) 18 (27.7) 15 (42.9) 0.124b
Coronary disease n (%) 4 (4) 3 (4.6) 1 (2.9) 1.000c
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0.01) (AUC = 73 %) (Table 2, Figs. 2, 3). These independ-
ent associations for E-selectin and VCAM-1 were main-
tained within the three subgroups after adjustment for
age and NIHSS (Fig. 4). Fourteen patients with ischemic
stroke were treated with recombinant tissue plasmino-
gen activator, of whom only four presented with a good
outcome. There is no modification of the model after ex-
clusion of these patients (data not shown). In view of
these results about inflammatory biomarkers, we were
interested in levels of matrix metalloproteinases
(MMP). We did not find any significant rise of
MMP-1 and MMP-3 levels between different times
and any significant difference between both patient
groups (Additional file 1).
Discussion
Inflammation is known to worsen cerebral damage at
the acute phase of stroke. The first step is represented
by the release of pro inflammatory cytokines from nec-
rotic cells like interleukin-1β (IL-1β) and tumor necrosis
factor (TNF-α). The direct results are activation of the
microglia and modification of permeability of the blood–
brain barrier [11]. Endothelial cells of the arterial wall
lose their tight junction and express CAMs [12]. These
later permit recruitment and migration of leukocytes
into the brain parenchyma [13]. Infiltration of cerebral
tissue with macrophages, neutrophil granulocytes and T-
cells has been demonstrated at different times following
experimental stroke [14]. First, adherence of leukocytes
to the arterial wall would contribute to microvessel ob-
struction [15]. More importantly, immune cells release
reactive oxygen species and MMP leading to cell death,
and cytokines maintaining inflammation [11]. This re-
sults in expansion of the infarction from the penumbra
and brain swelling. On the other hand, macrophages
permit clearance of necrotic debris and tissue repair by
production of tropic factors during later phases [2].
In this study, the early predictive capability of E-
selectin was specifically observed during the key period
of the first 6 h after stroke onset—the period during
which questions about reperfusion therapy arise.
VCAM-1 was an indicator of prognosis in a later
phase of patient management, with a significant in-
crease at 2–3 weeks. Both CAMs mediate adhesion of
the monocytes and granulocytes that participate in
the development of cerebral edema [7], whatever the
ischemic or hemorrhagic feature of cerebral damage
[5, 6]. E-selectin first recruits leukocytes rolling on
the vessel wall, whereafter a stronger adhesion is me-
diated by VCAM-1 [15]. This could explain their cor-
relation with prognosis at the acute phase of stroke,
early cytotoxic and vasogenic edema being responsible
Table 2 Biomarkers with significant higher levels in patients with 3-month poor outcome, univariate and ROC analysis
Biomarker Comparison mean concentrations+/−SD ROC curves Univariate analysis
Time Good outcome Poor outcome pa AUC (95 % CI) Cut-off OR (95 % CI) pb
E-selectin
0–6 h 26 ± 15 ng/mL 41 ± 19 ng/mL 0.004 78 % (61–95) 29 ng/mL 26 (4–165) 0.001
VCAM-1
2–3 weeks 669 ± 197 ng/mL 886 ± 284 ng/mL 0.003 73 % (59–88) 820 ng/mL 9 (3–33) 0.001
CRP
6–36 h 6 ± 13 mg/L 18 ± 26 mg/L 0.003 75 % (62–88) 5 mg/L 6 (2–18) 0.005
2–3 days 9 ± 15 mg/L 54 ± 68 mg/L <0.001 83 % (74–92) 7 mg/L 15 (4–49) <0.001
5–7 days 15 ± 53 mg/L 72 ± 101 mg/L <0.001 81 % (71–91) 9 mg/L 9 (3–26) <0.001
IL-6
2–3 days 50 ± 209 pg/mL 193 ± 819 pg/mL <0.001 75 % (64–87) 14 pg/mL 9 (3–25) <0.001
5–7 days 70 ± 274 pg/mL 21 ± 20 pg/mL 0.004 70 % (58–82) 4 pg/mL 12 (3–54) 0.002
NT-proBNP
6–36 h 1135 ± 2215 pg/mL 2547 ± 3286 pg/mL 0.002 76 % (65–88) 413 pg/mL 24 (3–200) 0.003
2–3 days 1254 ± 2235 pg/mL 3899 ± 7161 pg/mL 0.001 73 % (62–84) 314 pg/mL 18 (4–82) <0.001
5–7 days 1134 ± 2736 pg/mL 2055 ± 2557 pg/mL 0.001 73 % (62–84) 272 pg/mL 9 (3–26) <0.001
S100B
2–3 days 31 ± 57 pg/mL 336 ± 566 pg/mL 0.003 70 % (57–83) 30 pg/mL 5 (2–13) 0.001
SD standard deviation, ROC receiver operating characteristic analysis, AUC area under the curve, OR odds ratio, 95 % CI 95 % confidence interval; poor outcome
defined as modified Rankin Scale score > 2
aComparison of biomarkers levels between both groups, good and poor outcome, with Mann–Whitney U test, level of significance with Bonferroni
correction (p < 0.005)
bUnivariate analysis performed for biomarkers after determination of cut-off using ROC analysis
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for both the extension of the ischemic area and rising
intracranial hypertension [5]. They are both expressed
by endothelial cells, and VCAM-1 is also found in
smooth muscle cells [5, 16]. Expression of E-selectin
and VCAM-1 seems not to be concurrent in our
study. A first phase of CAMs synthesis occurs soon
after stroke onset, subsequent to vascular damage and
activation of the arterial wall [5, 17]. In vitro and in
vivo studies show E-selectin is the first to be released
by activated endothelial cells during the first 24 h
with rapid decrease [5, 18]. This permits initial re-
cruitment of granulocytes and monocytes by rolling
on activated endothelium. High levels of VCAM-1 are
found later in the blood and remain for several days
[5]. This corresponds to migration of monocytes
within brain parenchyma through VCAM-1. Such
high levels of E-selectin and VCAM-1 have been de-
scribed as decreasing within the first 4 days after
Fig. 1 Levels of biomarkers within the different time windows according to patients’ outcome. Levels of E-selectin (a), vascular cell adhesion
molecule-1 (b), C-reactive protein (c), interleukin-6 (d), and N-terminal pro-brain natriuretic peptide (e) are described as median, 25 and 75th
percentiles; difference between levels considered as significant for p < 0.005 (after Bonferroni correction)
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Fig. 2 Biomarkers significantly associated with 3-month poor outcome in multivariate analysis. Each biomarker separately adjusted for age and
National Institute of Health Stroke Scale at admission; OR, odds ratio; 95 % CI, 95 % confidence interval
Fig. 3 ROC analysis for biomarkers to predict 3-month poor outcome in patients with cerebrovascular diseases. Results for E-selectin at 0–6 h (a),
vascular cell adhesion molecule-1 at 2–3 weeks (b), N-terminal pro-brain natriuretic peptide at 6–36 h (c), C-reactive protein at 2–3 days (d), and
interleukin-6 at 2–3 days (e) are described as cut-off determined with Youden index criterion, respective specificity and sensitivity, area under the
curve (AUC) and 95 % confidence interval; poor outcome defined as modified Rankin Scale score > 2
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stroke onset, in association with the clinical improve-
ments seen in patients [8]. A second endothelial acti-
vation leads to the production of CAMs at the end of
the second week after stroke. This production could
participate in tissue remodeling, depending on the
volume of cerebral necrosis [5]. We observe at this
time high levels of VCAM-1 only, which could in
part explain its performance as a prognosis indicator
during the third week in our study. Moreover,
VCAM-1 is suspected to mediate inflammation in
atherosclerotic plaques, increasing the risk of rupture
and a recurrence of vascular events in stroke patients
[19]. It would also be involved in the arterial wall dis-
ease of cerebral lacunar infarctions due to hyperten-
sion [20]. During secondary analysis, we failed to find
any rise of MMP. These proteins are released by re-
cruited leukocytes and are implicated in brain damage
including blood–brain barrier disruption [21, 22].
However, we disposed of MMP-1 and 3 concentra-
tions only. Study of MMP-2 and 9, more described in
the cerebrovascular field, would be more relevant in
future works [23, 24].
The reliability of the present findings is supported by
the fact that the study confirms the predictive capability
of known biomarkers. During the third day following
stroke onset, two well-known proteins of the inflamma-
tory pathway—CRP and IL-6—were found to be indica-
tors of prognosis in our population. CRP is generated in
the liver, but it is also found in smooth muscle cells,
with a potential role in the growth and the rupture of
atherosclerotic plaques [25, 26]. Elevated levels of CRP
have been described from 3 h after stroke onset, with a
plasmatic peak between 36 and 48 h, and an ability to
predict outcome lasting several days [3]. Although IL-6
is a ubiquitous cytokine, it has been demonstrated that
its production is higher within 72 h of stroke onset, and
it has a key role at this stage of inflammatory response.
Production of IL-6 is induced by TNF-α and IL-1β, lead-
ing to a synthesis of CRP, fibrinogen and CAMs, activa-
tion of the hypothalamic-pituitary-adrenal axis, and
fever. CRP and IL-6 represent a further step along the
inflammatory pathway, promoting disruption of the
blood–brain barrier, edema, and vascular thrombosis [4].
They can also indicate a state of infection, a condition
that worsens the prognosis for patients with stroke. As a
result, both are already widely described as predictors of
poor outcome, mortality, and severity, including in cases
of ischemic [27, 28] or hemorrhagic strokes [29].
The NT-proBNP cardiac biomarker is the result of the
body metabolizing BNP—a vasoactive hormone secreted
by the ventricular myocardium subsequent to wall stress
and the stretching of myocytes. BNP plays a role in the
regulation of blood pressure via natriuretic, diuretic, and
vasodilatory effects. Higher levels are observed after the
first 24 h following stroke onset, especially in patients
with cardiac diseases like left ventricular failure and
Fig. 4 Multivariate analysis for association of E-selectin and vascular cell adhesion molecule-1 with 3-month poor outcome. Results in the total
population and subgroups; time windows 0–6 h for E-selectin (a), and 2–3 weeks for vascular cell ahesion molecule-1 (b); each biomarker separately
adjusted for age and National Institute of Health Stroke Scale (NIHSS) at admission; OR, odds ratio; 95 % CI, 95 % confidence interval; subgroup 1:
patients with ischemic events, i.e. excluding hemorrhagic strokes; subgroup 2: patients with cerebral damage, i.e. excluding transient ischemic attacks;
subgroup 3: patients with ischemic strokes, i.e. excluding hemorrhagic strokes and transient ischemic attacks
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arrhythmia, which are responsible for greater mortality
and the more serious, larger cerebral infarctions [30, 31].
NT-proBNP is considered as a predictor of cardioem-
bolic etiology [32], poor outcome [33], recurrence [16],
and mortality [34]. This biomarker can predict both evo-
lution during the acute phase and long term prognosis,
and it was found consistently in our results in the 6–36-
h period [35].
S100B is a calcium-binding protein found in the cen-
tral nervous system. Its presence in circulating blood is
an indication of disruption at the blood–brain barrier. It
is recognized as a biomarker of prognosis in stroke until
6 days after the event, resulting from its strong correl-
ation with infarction size and severity [36]. However,
after adjustment for age and NIHSS score, we failed to
find independent associations of S100B with poor
outcome.
One of this study’s aims was to select biomarkers pre-
dicting outcome in a population of patients combining
the most usual types of CVD. Indeed, in clinical practice,
a first blood sample is drawn early on during admission
of patients in order for urgent tests to be made, before
cerebral imaging and assessment of the final diagnosis.
This would be the appropriate time for a first measure-
ment of biomarkers, hence the interest in a common in-
dicator of prognosis, whatever the type of CVD. Our
study included patients with different types of CVDs,
with a distribution comparable to that encountered in
stroke units. However, the validity of determining bio-
markers for predicting prognosis in a heterogeneous
population combining CVDs of such different physiopa-
thology seemed questionable. We thus further validated
our results in subgroups with specific types of CVDs. E-
selectin and VCAM-1 remained independent predictors
of outcome in all three subgroups, as they did in the
overall population. An appropriate analysis could not
be performed on the subgroup of patients presenting
with hemorrhagic strokes because the sample size was
too small.
Furthermore, we studied large time windows instead
of specific endpoints; this was in order to help physi-
cians who need to assess a prognosis during periods
representing the different steps of a patient’s manage-
ment [37]. For instance, time of admission of patients
with stroke can vary widely, from the very acute phase,
when thrombolysis can be considered, until many hours
after onset for those patients who consult a physician
following a TIA or minor deficits.
This study has some limitations. Collection of data by
paramedical staff in non-consecutive cases resulted in a
lack of important information like evolution of NIHSS
score after the acute phase. The study’s limited sample
size did not allow us to estimate the added utility of E-
selectin and VCAM-1 measurement to predict outcome
using net reclassification improvement (NRI) and inte-
grated discrimination improvement (IDI). However,
multivariate analysis with adjustments for age and
NIHSS scores was used to select biomarkers presenting
the greatest correlations with outcome, and ROC ana-
lysis to assess their predictive ability. Face with
widespread values of proteins concentrations in the
population, we chose to determinate a cut-off for each
biomarker to assess association with outcome. This
method is more prone to overestimation of biomarker
accuracy, all the more in a limited sample size [38]. Fu-
ture studies should assess the predictive capability of
CAMs in a population with a homogenous initial clinical
state. This could identify, for example, patients at a high
risk of a worsening condition in cases of minor deficits,
or, on the other hand, patients with serious strokes who
are likely to improve. Such studies would require higher
numbers of patients in multiple centres.
Conclusions
The E-selectin and VCAM-1 CAMs were found to be
independent predictors of outcome in a population of
patients with CVD. The predictive capability of E-
selectin is valid during the first 6 h following a stroke,
while that of VCAM-1 is valid between the second and
third week. These biomarkers could be considered as
objective criteria and added to the clinical parameters of
future scores for prognosis of stroke.
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Additional file 1: Levels of matrix metalloproteinases within the
different time windows according to patients’ outcome. Levels of
matrix metalloproteinase 1 (a), and matrix metalloproteinase 3 (b) are
described as median, 25th and 75th percentiles; empty dots: good
outcome patient group, black-filled dots: bad outcome patient group.
(TIFF 88 kb)
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